Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,769 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,439 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,350)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00939328 | S0902 Bendamustine and Rituximab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Not Responded to Previous Treatment | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Mar 6, 2015 | clinicaltrials |
| NCT00042354 | Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients | completed | Phase 2 | 40 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 5, 2015 | clinicaltrials |
| NCT02373579 | Effect of Omega-3 Fatty Acids on Methotrexate Induced Hepatotoxicity in Children With Acute Lymphoblastic Leukemia | completed | Phase 2 | 70 | Nancy Samir ElbarbaryOTHER | 0 | Feb 27, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00916045 | Pilot Study of Unrelated Cord Blood Transplantation | terminated | Phase 2 | 40 | King's College Hospital NHS TrustOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01010373 | Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Patients | suspended | Phase 2 | 12 | BioMAS LtdINDUSTRY | 1 | Feb 10, 2015 | clinicaltrials |
| NCT00798213 | SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED) | terminated | Phase 2 | 29 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 4, 2015 | clinicaltrials |
| NCT01310101 | Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia | completed | Phase 2 | 33 | Brno University HospitalOTHER | 1 | Feb 3, 2015 | clinicaltrials |
| NCT00405054 | A Phase II Study of MK0457 in Patients With T315I Mutant CML and Ph+All (0457-008) | terminated | Phase 2 | 52 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jan 26, 2015 | clinicaltrials |
| NCT00560794 | Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) | completed | Phase 2 | 21 | Amgen Research (Munich) GmbHINDUSTRY | 1 | Jan 26, 2015 | clinicaltrials |
| NCT02339350 | Treatment of Newly Diagnosed High Risk Acute Lymphoblastic Leukemia in Children | unknown | Phase 2 | 110 | The Korean Society of Pediatric Hematology OncologyNETWORK | 1 | Jan 16, 2015 | clinicaltrials |
| NCT00114959 | Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML) | terminated | Phase 2 | 15 | ChemGenex PharmaceuticalsINDUSTRY | 1 | Jan 15, 2015 | clinicaltrials |
| NCT00002592 | Chemotherapy and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | completed | Phase 2 | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 14, 2015 | clinicaltrials |
| NCT00509249 | Aflibercept in Treating Patients With Myelodysplastic Syndromes | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jan 8, 2015 | clinicaltrials |
| NCT00528333 | A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML | completed | Phase 2 | 211 | Seagen Inc.INDUSTRY | 1 | Jan 7, 2015 | clinicaltrials |
| NCT00381550 | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 6, 2015 | clinicaltrials |
| NCT02275663 | Azacytidine Plus FLAG for Relapsed or Refractory AML | unknown | Phase 2 | 37 | King Fahad Medical CityOTHER_GOV | 1 | Jan 6, 2015 | clinicaltrials |
| NCT00661180 | Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec(ORACLE) | completed | Phase 2 | 10 | BayerINDUSTRY | 2 | Dec 23, 2014 | clinicaltrials |
| NCT00283101 | A Safety Study in Patients With Chronic Lymphocytic Leukemia | completed | Phase 1 / Phase 2 | 12 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00081055 | OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies | withdrawn | Phase 2 | 0 | Mesoblast International SàrlINDUSTRY | 1 | Dec 4, 2014 | clinicaltrials |
| NCT00858806 | Intermittent Imatinib Treatment in Chronic Myeloid Leukemia and Philadelphia Chromosome (Ph+CML) Patients Who Achieved a Complete Cytogenetic Response (CCgR) on Standard Imatinib Therapy(INTERIM0407) | completed | Phase 2 | 78 | Università degli Studi di BresciaOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT01800643 | Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation | unknown | Phase 2 / Phase 3 | 100 | Hospital Israelita Albert EinsteinOTHER | 1 | Dec 3, 2014 | clinicaltrials |
| NCT00907582 | ASCT for Relapsed APL After Molecular Remission | terminated | Phase 2 | 5 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Dec 2, 2014 | clinicaltrials |
| NCT00039377 | Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Nov 24, 2014 | clinicaltrials |
| NCT00388193 | Rituximab Combined With Chemotherapy in Burkitt's Lymphoma | completed | Phase 2 | 20 | PETHEMA FoundationOTHER | 1 | Oct 28, 2014 | clinicaltrials |
| NCT01465230 | Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia | terminated | Phase 2 | 2 | Yale UniversityOTHER | 1 | Oct 23, 2014 | clinicaltrials |
| NCT00795756 | Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 145 | Northern Italy Leukemia GroupOTHER | 1 | Oct 22, 2014 | clinicaltrials |
| NCT02270307 | MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis(MSC-CY) | unknown | Phase 2 / Phase 3 | 40 | National Research Center for Hematology, RussiaNETWORK | 1 | Oct 21, 2014 | clinicaltrials |
| NCT00602771 | Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Oct 9, 2014 | clinicaltrials |
| NCT01919866 | Safety Study of CD3/CD19 Depleted Haploidentical Stem Cells | unknown | Phase 1 / Phase 2 | 120 | University Children's Hospital TuebingenOTHER | 2 | Oct 8, 2014 | clinicaltrials |
| NCT00230282 | Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia | completed | Phase 2 | 25 | Steven E. CoutreOTHER | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00288067 | Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2014 | clinicaltrials |
| NCT00357500 | Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | completed | Phase 2 | 101 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2014 | clinicaltrials |
| NCT00546897 | Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Sep 29, 2014 | clinicaltrials |
| NCT00057811 | Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | completed | Phase 2 | 97 | Children's Oncology GroupNETWORK | 1 | Sep 19, 2014 | clinicaltrials |
| NCT00074737 | Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML | completed | Phase 2 | 53 | Eleos, Inc.INDUSTRY | 1 | Sep 18, 2014 | clinicaltrials |
| NCT00967512 | Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course | withdrawn | Phase 2 | 0 | Eleos, Inc.INDUSTRY | 0 | Sep 18, 2014 | clinicaltrials |
| NCT01290120 | Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma | completed | Phase 2 | 182 | Northern Italy Leukemia GroupOTHER | 1 | Sep 16, 2014 | clinicaltrials |
| NCT00593645 | Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | terminated | Phase 2 | 7 | Washington University School of MedicineOTHER | 1 | Sep 12, 2014 | clinicaltrials |
| NCT00742625 | Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 95 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2014 | clinicaltrials |
| NCT01435720 | Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) | unknown | Phase 1 / Phase 2 | 15 | Senesco Technologies, Inc.INDUSTRY | 2 | Sep 11, 2014 | clinicaltrials |
| NCT00589563 | Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer | completed | Phase 2 | 32 | City of Hope Medical CenterOTHER | 1 | Sep 10, 2014 | clinicaltrials |
| NCT00723203 | Panobinostat in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia | terminated | Phase 2 | 16 | City of Hope Medical CenterOTHER | 1 | Sep 9, 2014 | clinicaltrials |
| NCT00387647 | Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy | completed | Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 22, 2014 | clinicaltrials |
| NCT01472055 | Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation | unknown | Phase 2 | 46 | Seoul National University HospitalOTHER | 1 | Aug 20, 2014 | clinicaltrials |
| NCT00265915 | Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia | terminated | Phase 2 | — | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 0 | Aug 12, 2014 | clinicaltrials |
| NCT00021242 | Docetaxel in Treating Children With Relapsed or Refractory Acute Lymphoblastic or Acute Myeloid Leukemia | completed | Phase 2 | 12 | Children's Oncology GroupNETWORK | 7 | Aug 8, 2014 | clinicaltrials |
| NCT00003783 | Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia | completed | Phase 2 | 36 | Children's Oncology GroupNETWORK | 5 | Jul 28, 2014 | clinicaltrials |
| NCT00003178 | Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia | completed | Phase 2 | 120 | Children's Oncology GroupNETWORK | 7 | Jul 25, 2014 | clinicaltrials |
| NCT00003671 | Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphocytic Leukemia | completed | Phase 2 | 59 | Children's Oncology GroupNETWORK | 5 | Jul 25, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Mar 6, 2015source: clinicaltrials